Kamini N Reddy, Jignesh Shah, Shivakumar Iyer, Monidipa Chowdhury, Naveen Yerrapalem, Neeraja Pasalkar, Prashant P Jedge
{"title":"Direct Medical Cost Analysis of Indian COVID-19 Patients Requiring Critical Care Admission.","authors":"Kamini N Reddy, Jignesh Shah, Shivakumar Iyer, Monidipa Chowdhury, Naveen Yerrapalem, Neeraja Pasalkar, Prashant P Jedge","doi":"10.5005/jp-journals-10071-23991","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Intensive care unit (ICU) admission is required for approximately 25% of patients affected with coronavirus disease-19 (COVID-19) and imposes a high economic burden on patients in resource-limited settings.</p><p><strong>Method: </strong>We conducted a retrospective direct medical care cost analysis of COVID-19 patients requiring ICU admission after obtaining the Institutional Ethics Committee approval. Data were obtained from the records of patients admitted to the COVID-19 ICU of a tertiary care trust teaching hospital from June 2020 to December 2020. Direct costs were analyzed and correlated with various demographic variables and clinical outcomes.</p><p><strong>Results: </strong>A total of 176 patients were included (males-76%). The median direct medical cost for a median stay of 13 days was INR 202248.5 ($ 2742.91). Hospital drugs and disposables accounted for 20% of the total cost followed by bed charges (19%), equipment charges (17%), biosafety protective gear (15.5%), pathological and radiological tests (15%), clinical management (7.6%), and biomedical waste management (1.6%). Government schemes accounted for 79% of medical claims followed by directly paying patients (12.5%) and private insurance (8.5%). The cost was significantly higher in patients with diabetes mellitus and sepsis and in those requiring mechanical ventilation (MV) (<i>p</i> <0.05). Shorter lead time to hospital admission and lesser length of hospital stay were associated with significant lower direct cost.</p><p><strong>Conclusion: </strong>Direct medical care cost is substantial for COVID-19 patients requiring ICU admission. This cost is significantly associated with increased ICU and hospital stay, longer lead time to admission, diabetes mellitus, sepsis, and those who need high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), and MV.</p><p><strong>How to cite this article: </strong>Reddy KN, Shah J, Iyer S, Chowdhury M, Yerrapalem N, Pasalkar N, <i>et al</i>. Direct Medical Cost Analysis of Indian COVID-19 Patients Requiring Critical Care Admission. Indian J Crit Care Med 2021;25(10):1120-1125.</p>","PeriodicalId":520643,"journal":{"name":"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine","volume":" ","pages":"1120-1125"},"PeriodicalIF":1.5000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/88/ijccm-25-1120.PMC8645812.pdf","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10071-23991","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7
Abstract
Introduction: Intensive care unit (ICU) admission is required for approximately 25% of patients affected with coronavirus disease-19 (COVID-19) and imposes a high economic burden on patients in resource-limited settings.
Method: We conducted a retrospective direct medical care cost analysis of COVID-19 patients requiring ICU admission after obtaining the Institutional Ethics Committee approval. Data were obtained from the records of patients admitted to the COVID-19 ICU of a tertiary care trust teaching hospital from June 2020 to December 2020. Direct costs were analyzed and correlated with various demographic variables and clinical outcomes.
Results: A total of 176 patients were included (males-76%). The median direct medical cost for a median stay of 13 days was INR 202248.5 ($ 2742.91). Hospital drugs and disposables accounted for 20% of the total cost followed by bed charges (19%), equipment charges (17%), biosafety protective gear (15.5%), pathological and radiological tests (15%), clinical management (7.6%), and biomedical waste management (1.6%). Government schemes accounted for 79% of medical claims followed by directly paying patients (12.5%) and private insurance (8.5%). The cost was significantly higher in patients with diabetes mellitus and sepsis and in those requiring mechanical ventilation (MV) (p <0.05). Shorter lead time to hospital admission and lesser length of hospital stay were associated with significant lower direct cost.
Conclusion: Direct medical care cost is substantial for COVID-19 patients requiring ICU admission. This cost is significantly associated with increased ICU and hospital stay, longer lead time to admission, diabetes mellitus, sepsis, and those who need high-flow nasal cannula (HFNC), noninvasive ventilation (NIV), and MV.
How to cite this article: Reddy KN, Shah J, Iyer S, Chowdhury M, Yerrapalem N, Pasalkar N, et al. Direct Medical Cost Analysis of Indian COVID-19 Patients Requiring Critical Care Admission. Indian J Crit Care Med 2021;25(10):1120-1125.
大约25%的冠状病毒病-19 (COVID-19)患者需要入住重症监护病房(ICU),在资源有限的环境中,这给患者带来了沉重的经济负担。方法:在获得机构伦理委员会批准后,对需要ICU住院的COVID-19患者进行回顾性直接医疗成本分析。数据来自某三级医疗信托教学医院2020年6月至2020年12月COVID-19重症监护室收治的患者记录。对直接成本进行分析,并将其与各种人口统计学变量和临床结果相关联。结果:共纳入176例患者(男性76%)。住院13天的直接医疗费用中位数为202248.5印度卢比(2742.91美元)。医院药品和一次性用品占总费用的20%,其次是床位费(19%)、设备费(17%)、生物安全防护装备(15.5%)、病理和放射检查(15%)、临床管理(7.6%)和生物医学废物管理(1.6%)。政府计划占医疗索赔的79%,其次是直接支付病人(12.5%)和私人保险(8.5%)。糖尿病和脓毒症患者以及需要机械通气(MV)的患者的直接医疗费用明显高于其他患者(p)。该费用与ICU和住院时间增加、入院前时间延长、糖尿病、败血症以及需要高流量鼻插管(HFNC)、无创通气(NIV)和MV的患者显著相关。本文摘自:Reddy KN, Shah J, Iyer S, Chowdhury M, Yerrapalem N, Pasalkar N,等。印度COVID-19重症患者直接医疗成本分析中华检验医学杂志;2011;25(10):1120-1125。